The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash ...

CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...

In a report released today, Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report), ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States Immunotherapy stands as the frontrunner ...

This is a randomized open label multicenter trial of Vepdeg versus fulvestrant in patients with ... including the approved CDK4.6 inhibitors ribociclib and abemaciclib in the ongoing Phase 1D2 ...

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive ...

2-5 Median PFS (mPFS) in the PALOMA-2 (palbociclib plus letrozole), MONALEESA-2 (ribociclib plus letrozole), MONALEESA ... combining everolimus with either fulvestrant or exemestane, or fulvestrant ...

Ribociclib (Kisqali) is the only CDK4/6i recommended for ... treatment of adults with HR+/HER2- advanced or MBC in combination with an AI as initial ET or fulvestrant as initial ET or following ...

ribociclib (Kisqali) is also recommended as a Category 1 preferred regimen for first- and subsequent-line therapies in HR+/HER2- MBC in combination with fulvestrant. NCCN makes no warranties of any ...